Current Evidence for Neuroprotective Effects of Nicotine and Caffeine Against Parkinson??s Disease
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in Drugs & Aging
- Vol. 18 (11) , 797-806
- https://doi.org/10.2165/00002512-200118110-00001
Abstract
Parkinson’s disease (PD) is the second most common neurodegenerative disorder affecting 1 to 3% of individuals over the age of 65 years. While effective therapy exists for treating the bradykinesia,...Keywords
This publication has 102 references indexed in Scilit:
- In vitro and in vivo studies investigating possible antioxidant actions of nicotine: relevance to Parkinson’s and Alzheimer’s diseasesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1999
- Adenosine A2A Receptors and NeuroprotectionAnnals of the New York Academy of Sciences, 1997
- Nicotinic System Involvement in Alzheimer??s and Parkinson??s DiseasesDrugs & Aging, 1997
- Nicotine modulates the neurotoxic effect of β-amyloid protein(25–35) in hippocampal culturesNeuroReport, 1997
- Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spuriousBritish Medical Bulletin, 1996
- CGS 15943, An adenosine A2 receptor antagonist, reduces cerebral ischemic injury in the mongolian gerbilLife Sciences, 1994
- Cortical cerebral blood flow governed by the basal forebrain: Age-related ImpairmentsNeurobiology of Aging, 1991
- Akinesia due to catecholamine depletion in mice is prevented by caffeine. Further evidence for an involvement of adenosinergic system in the control of motilityJournal of Pharmacy and Pharmacology, 1991
- Chronic administration of nicotine fails to alter the MPTP-induced neurotoxicity in miceGeneral Pharmacology: The Vascular System, 1991
- Effect of Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1989